Ftse Mib
33.825,67
0,23%
DAX
17.914,48
-0,04%
S&P 500
5.018,39
-0,34%
NASDAQ Composite
15.605,48
-0,33%
Bitcoin
57.860,16
-0,65%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. AMEX Oragenics Inc (OGEN) Oragenics Inc (OGEN) Notizie

Oragenics Inc

OGEN
1,02
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 10:09:42
Dati in Delay di 15 minuti
Borsa: AMEX
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
19/4/202423:50BWOragenics, Inc. Announces Notification of Noncompliance with..
01/4/202415:05BWOragenics, Inc. Files 10K and Provides Company Update
18/3/202412:00BWOragenics Appoints James Kelly MD, Chief Medical Officer, to..
06/3/202422:24EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/3/202413:45BWOragenics, Inc. Prepares Drug for Phase II Clinical Trials..
01/3/202422:04BWOragenics Announces Closing of Public Offering
29/2/202422:41EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/2/202415:03EDGAR2Form 8-K - Current report
28/2/202403:25BWOragenics Announces Pricing of Public Offering
27/2/202423:09EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
27/2/202423:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
27/2/202422:33BWOragenics Announces Proposed Public Offering
13/2/202402:06EDGAR2Form SC 13D - General statement of acquisition of beneficial..
12/2/202422:45EDGAR2Form 8-K - Current report
12/2/202422:41BWOragenics, Inc. Announces Leadership Transition
07/2/202414:00EDGAR2Form 8-K - Current report
07/2/202414:00BWOragenics, Inc. Announces Expiration of Its Investment..
05/2/202414:00EDGAR2Form 8-K - Current report
05/2/202414:00BWOragenics, Inc. Preparing for Phase II Clinical Trials to..
23/1/202423:34BWOragenics Announces Termination of At-The-Market Offering..
23/1/202423:18EDGAR2Form 8-K - Current report
22/1/202423:30EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
16/1/202415:10EDGAR2Form 8-K - Current report
16/1/202415:08EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
16/1/202415:04EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/1/202422:37EDGAR2Form S-8 - Securities to be offered to employees in employee..
02/1/202423:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202415:22EDGAR2Form 8-K - Current report
02/1/202413:30BWOragenics Completes Acquisition of Odyssey Health’s..
29/12/202313:30EDGAR2Form 8-K - Current report
15/12/202321:45EDGAR2Form 8-K - Current report
08/12/202322:00EDGAR2Form 8-K - Current report
01/12/202323:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/11/202323:50EDGAR2Form 144 - Report of proposed sale of securities
20/11/202321:45EDGAR2Form 8-K - Current report
16/11/202320:37EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
02/11/202312:00EDGAR2Form 8-K - Current report
02/11/202312:00EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
02/11/202312:00BWOragenics Issues Update to Shareholders
30/10/202321:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
30/10/202321:00EDGAR2Form DEF 14A - Other definitive proxy statements
18/10/202314:30BWOragenics Announces Appointment of Bruce Cassidy and John..
06/10/202322:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202322:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202322:28EDGAR2Form 3 - Initial statement of beneficial ownership of..
06/10/202322:25EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/10/202323:29EDGAR2Form 8-K - Current report
05/10/202312:30EDGAR2Form 8-K - Current report
05/10/202312:30BWOragenics to Acquire Odyssey Health’s Neurological Drug..
29/9/202322:00EDGAR2Form 8-K - Current report
Apertura: Min: Max:
Chiusura: 1,02

La tua Cronologia

AMEX
OGEN
Oragenics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network